Full-Time

Quality Control Laboratory Operations Lead

Deadline 7/28/27
WuXi AppTec

WuXi AppTec

1,001-5,000 employees

Global contract research, development, manufacturing organization

No salary listed

Middletown, DE, USA

In Person

Bachelor's

Category
Biology & Biotech (1)
Required Skills
Inventory Management
Metrology
GMP

Get referred to WuXi AppTec

See people who can refer or advise you

Requirements
  • A bachelor's degree in Chemistry, Biology, Pharmaceutical Sciences, Engineering, or a related scientific discipline is required.
  • A minimum of 7 years of Good Manufacturing Practice pharmaceutical laboratory experience, including at least 3 years in leadership or supervisory roles, is required.
  • Demonstrated experience managing laboratory operations, stability programs, sample management, metrology, equipment programs, or laboratory systems is required.
  • Strong understanding of Good Manufacturing Practice regulations, data integrity principles (ALCOA+), and regulatory inspection expectations is required.
  • Experience with Laboratory Information Management Systems, Chromatography Data Systems, stability management software, inventory systems, and computerized system compliance is required.
  • Ability to manage multiple priorities in a fast-paced pharmaceutical manufacturing environment is required.
  • Strong organizational, communication, project management, and leadership skills are required.
Responsibilities
  • Own and manage the site stability program, including study initiation, sample pulls, scheduling, storage, inventory tracking, and sample reconciliation.
  • Ensure stability studies are executed in accordance with approved protocols, regulatory requirements, and client commitments.
  • Coordinate stability chamber utilization, monitoring, qualification activities, and capacity planning.
  • Maintain stability databases and ensure accurate tracking of all stability samples throughout the study lifecycle.
  • Monitor program performance and ensure timely communication of upcoming testing requirements.
  • Lead laboratory sample management operations from receipt through storage, distribution throughout the testing groups, reconciliation, retention, and disposal.
  • Develop and maintain procedures governing sample custody, chain of custody documentation, and sample traceability.
  • Manage sample logistics supporting release testing, stability testing, investigations, validation activities, and client requests.
  • Ensure sample inventory systems are maintained accurately and support efficient laboratory workflows.
  • Identify and implement improvements to sample handling processes that enhance compliance and operational efficiency.
  • Oversee the full lifecycle management of laboratory equipment, including procurement, commissioning, qualification, calibration, preventive maintenance, repair, and retirement.
  • Manage equipment scheduling to ensure continuous laboratory readiness and minimize downtime.
  • Partner with Validation, Engineering, and vendors to support instrument qualification and maintenance activities.
  • Ensure calibration and maintenance programs are executed within established due dates.
  • Monitor equipment performance metrics and drive continuous improvement initiatives.
  • Monitor vendor performance metrics and implement contingency plans where necessary to ensure there is no disruption to throughput.
  • Maintain equipment inventory records and ensure compliance with applicable Good Manufacturing Practice requirements.
  • Establish and manage laboratory inventory programs for reagents, consumables, reference standards, columns, and critical supplies.
  • Monitor inventory levels and implement forecasting processes to ensure uninterrupted laboratory operations.
  • Coordinate purchasing activities and maintain appropriate stock levels while minimizing waste and expired materials.
  • Ensure materials are received, stored, qualified, and utilized according to approved procedures.
  • Develop key performance metrics related to inventory utilization, availability, and cost management.
  • Lead a small team of dedicated contractors supporting consumable materials.
  • Serve as business owner or system administrator for critical laboratory computerized systems, including Laboratory Information Management Systems, Chromatography Data Systems, Electronic Laboratory Notebooks, and related Good Manufacturing Practice applications.
  • Coordinate system access management, user administration, configuration changes, periodic reviews, and data integrity activities.
  • Partner with Information Technology, Quality Assurance, and system vendors to maintain system compliance and operational effectiveness.
  • Support computer system validation activities and change control processes.
  • Ensure regulatory compliance with data integrity requirements and maintain inspection readiness for all laboratory systems.
  • Ensure laboratory operational processes comply with Food and Drug Administration, European Medicines Agency, International Council for Harmonisation, and applicable Good Manufacturing Practice regulations.
  • Support investigations, deviations, corrective and preventive actions, change controls, and risk assessments associated with laboratory operations.
  • Participate in internal audits, client audits, and regulatory inspections.
  • Monitor compliance trends and implement preventive actions to reduce operational risk.
  • Drive continuous improvement initiatives to improve efficiency, compliance, and employee engagement.
  • Build, develop, and lead the Laboratory Operations team.
  • Provide coaching, mentoring, training, and career development opportunities for team members.
  • Establish performance expectations and conduct routine performance evaluations.
  • Manage staffing, resource allocation, and succession planning.
  • Foster a culture focused on compliance, operational excellence, accountability, and continuous improvement.
Desired Qualifications
  • An advanced degree is preferred.

What WuXi AppTec does: It provides a global, integrated open-access platform for contract research, development, and manufacturing services (CRDMO) to the pharmaceutical, biotechnology, and medical device industries. How its products work: Clients access a broad portfolio of capabilities—laboratory testing, process development, and manufacturing—across the full product lifecycle, from discovery and preclinical work to clinical and commercial production, often supported by strategic acquisitions to extend reach. How it differs from competitors: It combines extensive geographic reach with a wide, end-to-end service portfolio in one platform, rather than focusing on a narrow stage or region. What its goal is: To help innovators bring new medicines and healthcare products to market faster and with high quality.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Huangpu, China

Founded

2000

Get referred to WuXi AppTec

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • WuXi AppTec raised 2026 revenue guidance to RMB 58.5-60.5 billion on August 3, 2026.
  • H1 2026 revenue rose 38.9%, and backlog reached RMB 66.43 billion.
  • Delaware starts Q4 2026 and Singapore starts 2027, expanding non-China manufacturing capacity.

What critics are saying

  • On June 8, 2026, DoD added WuXi AppTec to the 1260H Chinese military list.
  • Customers terminated, paused, and redirected programs within weeks after the June 2026 designation.
  • If BIOSECURE targets WuXi in December 2026, U.S. business continuity faces existential damage.

What makes WuXi AppTec unique

  • WuXi AppTec’s integrated CRDMO spans discovery, development, and manufacturing across 30-plus countries.
  • Its 2026 capacity buildout covers Delaware, Singapore, Taixing, and Switzerland simultaneously.
  • DMPK compound management serves thousands of clients with one-million-plus compound storage and traceability.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
PR Newswire
Aug 3rd, 2026
WuXi AppTec H1 revenue surges 39% to $4B, raises 2026 guidance amid US defence list inclusion

WuXi AppTec reported strong first-half 2026 results and raised its full-year guidance. The Chinese pharmaceutical contract research, development, and manufacturing organisation posted H1 revenue of RMB 28.90 billion, up 38.9% year-on-year, with continuing operations revenue rising 48.0%. Adjusted non-IFRS net profit increased 83.2% to RMB 11.57 billion, whilst the gross profit margin expanded 9.4 percentage points to 53.9%. The company's backlog for continuing operations grew 25.2% to RMB 66.43 billion as of 30 June 2026. WuXi AppTec raised its 2026 total revenue target to RMB 58.5–60.5 billion, up from RMB 51.3–53.0 billion previously. The firm also increased its capital expenditure guidance to RMB 7.5–8.5 billion to support accelerated global capacity expansion. The company addressed its inclusion on the US Department of Defence's 1260H list, calling it erroneous and confirming legal action to protect stakeholder interests.

Associated Press
Jul 7th, 2026
WuXi AppTec launches automated compound management system with fourfold storage density and full traceability

WuXi AppTec DMPK has launched an automated compound management platform serving thousands of pharmaceutical and biotechnology companies worldwide, with storage capacity exceeding one million compounds. The system provides full lifecycle management through digital operations, featuring automated robotic retrieval, real-time weighing data integration with high-precision balances, and automated preparation via Hamilton systems. The platform addresses three major challenges in drug metabolism and pharmacokinetics research: diverse container types, large compound libraries, and strict storage requirements. Key capabilities include real-time logistics tracking, image recognition-based automated picking, and high-density mobile storage delivering approximately fourfold capacity versus fixed-cabinet layouts. The system maintains tamper-proof audit logs and role-based access control whilst integrating with the Mosaic Compound Management System. WuXi AppTec DMPK offers flexible managed services covering sample receipt, secure storage, distribution, and disposal, aiming to reduce operational costs and accelerate research timelines.

Associated Press
Jun 11th, 2026
WuXi AppTec expands peptide and oligonucleotide capacity, eyes 40% revenue growth in 2026

WuXi AppTec is expanding its global manufacturing capabilities for emerging drug modalities including peptides, oligonucleotides and targeted protein degraders, according to Pharma Manufacturing. The company's WuXi TIDES platform, focused on oligonucleotides and peptides, is projected to achieve approximately 40% year-on-year revenue growth in 2026. The company's solid-phase peptide synthesis reactor volume exceeded 100,000 litres at end-2025 and is expected to reach 130,000 litres by end-2026. New production facilities are under construction in Taixing, China, scheduled for 2027 operation, and Singapore, planned for 2028. WuXi AppTec is investing in process technologies combining solid-phase and liquid-phase synthesis to improve scalability for complex molecules. The company is also developing integrated approaches for antibody-drug conjugates and targeted protein degraders, incorporating earlier-stage chemistry and biology integration.

Yahoo Finance
Jun 9th, 2026
WuXi AppTec added to Pentagon's Chinese military list, vows to challenge 'erroneous designation

WuXi AppTec has been added to the Pentagon's list of "Chinese military companies", escalating tensions between the pharmaceutical manufacturer and the US. The Department of Defence updated its Section 1260H list on 8 June, adding WuXi alongside other Chinese firms including BYD and Comac. The DoD claims WuXi has links to China's State Administration for Science, Technology and Industry for National Defence and the People's Liberation Army. WuXi strongly denied the designation, calling it "clearly a mistake" and stating it is not owned, controlled or affiliated with any Chinese military or government entity. The contract research and manufacturing organisation, which operates in over 30 countries, reported revenues of $1.83 billion in Q1 2026, up 39.4% year-over-year. WuXi was previously removed from the BIOSECURE Act in October 2025.

Associated Press
Jun 5th, 2026
WuXi AppTec boosts capex 17% to $77M-$89M for global manufacturing expansion

WuXi AppTec is accelerating global manufacturing expansion across the United States, Europe and Asia, increasing capital expenditures by at least 17% this year to between RMB 6.5 billion and RMB 7.5 billion. The pharmaceutical contract research, development and manufacturing organisation is responding to growing customer demand, particularly for peptides and oligonucleotides. The company's new Middletown, Delaware facility will begin oral solid dosage manufacturing in Q4 2026, becoming its largest US site at 1.74 million square feet. In Europe, WuXi is expanding its Couvert, Switzerland site, whilst a Singapore facility is expected to begin Phase I operations in 2027. WuXi AppTec's small molecule pipeline reached 3,550 molecules by end-March 2026. Its TIDES business is projected to grow approximately 40% year-over-year.